Clinical Features and Quality of Life in End Stage Renal Disease Patients Undergoing Hemodialysis Twice A Week Compared toThrice A Week

Abstract

Introduction The optimal hemodialysis (HD) frequency for patients with end-stage renal disease (ESRD) remains a subject of debate, with significant implications for clinical outcomes and quality of life (QoL). This literature review synthesizes recent evidence comparing the clinical features and patient-reported outcomes of twice-weekly versus thrice-weekly HD regimens.

Methods This comprehensive review analyzes six key articles published between 2020 and 2022, examining the safety, efficacy, and QoL impact of different HD frequencies. The analysis considers factors such as residual renal function (RRF), patient-reported outcomes, and socioeconomic contexts in which treatment is delivered.

Results The evidence is conflicting. Some studies suggest that twice-weekly HD is a safe initial strategy that may better preserve RRF, a key prognostic factor for survival. Conversely, other research indicates that patients on more frequent, thrice-weekly HD report better health-related QoL. However, some studies found no significant difference in QoL scores between the two regimens , highlighting the influence of economic constraints, intradialytic symptoms, and recovery times.

Discussion The conflicting findings suggest a universal standard for HD frequency is inappropriate. The decision between twice-weekly and thrice-weekly regimens involves a trade-off between potential QoL benefits, preservation of RRF, and practical considerations like socioeconomic factors. This underscores the need for a holistic, patient-centered approach rather than focusing on frequency alone.

Conclusion Optimal HD frequency is multifactorial. While thrice-weekly HD may offer some QoL advantages, twice-weekly HD is a viable and sometimes preferable option, particularly for preserving RRF and in resource-limited settings. Clinical practice must prioritize individualized care plans that integrate patient-reported outcomes, clinical status, and RRF.